40.40
+1.61(+4.15%)
Currency In USD
Address
Building No. 2
San Diego, CA 92121
United States of America
Phone
858 450 6464
Website
Sector
Healthcare
Industry
Biotechnology
Employees
290
First IPO Date
July 18, 2018
| Name | Title | Pay | Year Born |
| Dr. R. Scott Struthers Ph.D. | Founder, President, Chief Executive Officer & Director | 978,339 | 1963 |
| Mr. Marc J. C. Wilson CPA | Chief Financial Officer | 642,252 | 1980 |
| Dr. Alan S. Krasner M.D. | Chief Endocrinologist | 653,924 | 1963 |
| Mr. Jeff E. Knight | Chief Operating Officer | 657,312 | 1971 |
| Dr. Stephen F. Betz Ph.D. | Founder & Chief Scientific Officer | 672,664 | 1966 |
| Mr. Kevin Capps | Head of Intellectual Property | 0 | N/A |
| Ms. Garlan Adams | General Counsel & Corporate Secretary | 0 | N/A |
| Gayathri Diwakar | Head of Investor Relations | 0 | N/A |
| Ms. Adriana Cabre M.B.A. | Chief Human Resources Officer | 0 | N/A |
| Mr. Chris Robillard M.B.A. | Chief Business Officer | 0 | N/A |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.